The Future of Anticoagulation

 

 Buy Article Permissions and Reprints

ABSTRACT

The conventional management of thrombotic disorders is based on the use of heparin, oral anticoagulants, and aspirin. The development of low molecular weight heparins and the synthesis of heparinomimetics such as the chemically synthesized pentasaccharide represent a refined use of heparin. Aspirin still remains the lead drug in the management of thrombotic and cardiovascular disorders. The newer antiplatelet drugs such as the adenosine diphosphate receptor inhibitors, glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors and other specific inhibitors have limited effects and have been tested in patients who have already been treated with aspirin. The oral anticoagulants such as warfarin provide a convenient and affordable approach in the long-term outpatient management of thrombotic disorders. The optimized use of these drugs still remains the approach of choice to manage thrombotic disorders. The new anticoagulant drugs target specific sites in the hemostatic network. There is a major thrust on the development of orally bioavailable anticoagulant drugs to replace oral anticoagulants. Heparin and low molecular weight heparins have been considered with various chemical enhancers for absorption. Both the factor Xa and antithrombin agents have been developed for oral use and some of these agents are in clinical development. Besides the limited bioavailability, the therapeutic indices of some of these drugs have been rather disappointing. Factor Xa inhibitors such as the pentasaccharides have undergone aggressive clinical development. The newer antiplatelet drugs have added a new dimension in the management of thrombotic disorders. The newer drugs are attractive for several reasons; however, none of these are expected to completely replace the conventional drugs in polytherapeutic approaches. It is conceivable that some of the newer drugs in combined modalities may mimic the broad therapeutic spectrum of heparins and warfarin. However, clinical validation is required for the therapeutic interchange for specific indications.

REFERENCES

• 1 Fareed J, Lewis B E, Callas D D et al.. Antithrombin agents: the new class of anticoagulant and antithrombin drug.  Clin Appl Thromb Hemost. 1999;  5(Suppl 1) S45-S55
  CrossrefPubMedGoogle Scholar
• 2 Fareed J, Haas S, Sasahara A. Differentiation of low molecular weight heparins: applied and clinical considerations.  Semin Thromb Hemost. 1999;  25(Suppl 3) 1-47
  PubMedGoogle Scholar
• 3 Fareed J, Messmore H L. Clopidogrel, a new ADP receptor antagonist: clinical development.  Semin Thromb Hemost.. 1999;  25(Suppl 2) 1-84
  PubMedGoogle Scholar
• 4 Fareed J, Walenga J M, Hoppensteadt D, Kaiser B, Jeske W. Factor Xa inhibitors in the control of thrombogenesis.  Hämostaseologie. 1999;  19 55-62
  PubMedGoogle Scholar
• 5 Bick R L, Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States.  Clin Appl Thromb Hemost. 1999;  5(Suppl 1) S63-S66
  PubMedGoogle Scholar
• 6 Fareed J, Hoppensteadt D. The management of thrombotic and cardiovascular disorders in the 21st century. In: Sasahara AA, Loscalzo J New Therapeutic Agents in Thrombosis and Thrombolysis. New York; Marcel Dekker 2005: 687-693
  Google Scholar
• 7 Albers G W, Amarenco P, Easton J D et al.. Antithrombotic and thrombolytic therapy for ischemic stroke: the seventh ACCP conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126(Suppl 3) 483S-512S
  CrossrefPubMedGoogle Scholar
• 8 Harrington R A, Becker R C, Ezekowitz M et al.. Antithrombotic therapy for coronary artery disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126(Suppl 3) 513S-548S
  CrossrefPubMedGoogle Scholar
• 9 Popma J J, Berger P, Ohman E M et al.. Antithrombotic therapy during percutaneous coronary intervention: the seventh ACCP conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126(Suppl 3) 576S-599S
  CrossrefPubMedGoogle Scholar
• 10 Geerts W H, Pineo G F, Heit J A et al.. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126(Suppl 3) 338S-400S
  CrossrefPubMedGoogle Scholar
• 11 Fenton J W. Regulation of thrombin generation and functions.  Semin Thromb Hemost. 1988;  14 234-240
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Di Nisio M, Middeldorp S, Buller H R. Direct thrombin inhibitors.  N Engl J Med. 2005;  353 1028-1040
  CrossrefPubMedGoogle Scholar
• 13 Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic.  Curr Top Med Chem. 2005;  5 1677-1695
  CrossrefPubMedGoogle Scholar
• 14 Lubenow N, Eichler P, Lietz T et al.. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.  Blood. 2004;  104 3072-3077
  CrossrefPubMedGoogle Scholar
• 15 Lewis B E, Wallis D E, Berkowitz S D et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103 1838-1843
  CrossrefPubMedGoogle Scholar
• 16 Lewis B E, Wallis D E, Leya F et al.. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856
  CrossrefPubMedGoogle Scholar
• 17 Eriksson B I, Wille-Jorgensen P, Kalebo P et al.. A comparison of recombinant hirudin with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med. 1997;  337 1329-1335
  CrossrefPubMedGoogle Scholar
• 18 Eriksson B I, Ekman S, Lindbratt S et al.. Prevention of thromboembolism with use of recombinant hirudin: results of a double blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.  J Bone Joint Surg Am. 1997;  79 326-333
  PubMedGoogle Scholar
• 19 Carswell C I, Plosker G L. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.  Drugs. 2002;  62 841-870
  CrossrefPubMedGoogle Scholar
• 20 Ahrens I, Smith B K, Bode C, Peter K. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.  Expert Opin Drug Metab Toxicol. 2007;  3 609-620
  CrossrefPubMedGoogle Scholar
• 21 Carswell C I, Plosker G L. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.  Drugs. 2002;  62 841-870
  CrossrefPubMedGoogle Scholar
• 22 Dyke C M, Aldea G, Koster A et al.. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies.  Ann Thorac Surg. 2007;  84 836-839
  CrossrefPubMedGoogle Scholar
• 23 Pappalardo F, Franco A, Crescenzi G et al.. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy.  Perfusion. 2007;  22 67-69
  CrossrefPubMedGoogle Scholar
• 24 Leone G, Rossi E, Leone A M, De Stefano V. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors: evidences from clinical studies.  Curr Med Chem Cardiovasc Hematol Agents. 2004;  2 311-326
  CrossrefPubMedGoogle Scholar
• 25 Bauer K A. New anticoagulants.  Hematology Am Soc Hematol Educ Program. 2006;  450-456
  PubMedGoogle Scholar
• 26 LaMonte M P, Nash M L, Wang D Z et al.. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study.  Stroke. 2004;  35 1677-1682
  CrossrefPubMedGoogle Scholar
• 27 Eriksson B I, Dahl O E, Buller H et al.. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.  J Thromb Haemost. 2005;  3 103-111
  CrossrefPubMedGoogle Scholar
• 28 Samama M M, Walenga J, Kaiser B, Fareed J. Specific factor Xa inhibitors. In: Verstraete M, Fuster V, Topol E Cardiovascular Thrombosis: Thrombocardiology. Brussels; Lippincott-Raven 1997: 173-188
  Google Scholar
• 29 Weitz J I, Hirsh J. New antithronbotic agents.  Chest. 2001;  119 95S-107S
  CrossrefPubMedGoogle Scholar
• 30 Walenga J M, Jeske W P, Samama M M et al.. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.  Expert Opin Investig Drugs. 2002;  11 397-407
  CrossrefPubMedGoogle Scholar
• 31 Lassen M R, Bauer K A, Eriksson B I et al.. Postoperative fondaparinux versus preoperative enoxaparin for the prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison.  Lancet. 2002;  359 1715-1720
  CrossrefPubMedGoogle Scholar
• 32 Turpie A GG, Bauer K A, Erikkson B I et al.. Postoperative fondaparinux versus preoperative enoxaparin for the prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison.  Lancet. 2002;  359 1721-1726
  CrossrefPubMedGoogle Scholar
• 33 Bauer K A, Eriksson B I, Lassen M R et al.. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med. 2001;  345 1305-1310
  CrossrefPubMedGoogle Scholar
• 34 Eriksson B I, Bauer K A, Lassen M R et al.. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.  N Engl J Med. 2001;  345 1298-1304
  CrossrefPubMedGoogle Scholar
• 35 Buller H R, Davidson B L, Decousus H et al.. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.  Ann Intern Med. 2004;  140 867-873
  PubMedGoogle Scholar
• 36 Buller H R, Davidson B L, Decousus H et al.. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.  N Engl J Med. 2003;  349 1695-1702
  CrossrefPubMedGoogle Scholar
• 37 Simoons M L, Bobbink I W, Boland J et al.. A dose-finding study of fondaparinux in patients with non-ST-segment elevation in acute coronary syndromes. The Pentasaccharide in Unstable Angina (PENTUA) Study.  J Am Coll Cardiol. 2004;  43 2183-2190
  CrossrefPubMedGoogle Scholar
• 38 Yusuf S, Mehta S R, Chrolavicius S et al.. Comparison of fondaparinux with enoxaparin in acute coronary syndromes.  N Engl J Med. 2006;  354 1464-1476
  CrossrefPubMedGoogle Scholar
• 39 Herbert J M, Heravlet J P, Bernat A et al.. Biochemical and pharmacologic properties of SanOrg 34006, a potent and long-acting synthetic pentasaccharide.  Blood. 1998;  91 4197-4205
  PubMedGoogle Scholar
• 40 PERSIST Investigators . A novel, long-acting synthetic factor Xa inhibitor (SanOrg 34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation.  J Thromb Haemost. 2004;  2 47-53
  CrossrefPubMedGoogle Scholar
• 41 Murayama T, Tanaka M, Kunitada S et al.. Tolerability, pharmacokinetics and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.  Clin Pharmacol Ther. 1999;  66 258-264
  PubMedGoogle Scholar
• 42 Dyke C K, Becker R C, Kleiman N S et al.. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.  Circulation. 2002;  105(20) 2385-2391
  CrossrefPubMedGoogle Scholar
• 43 Turpie A G, Fisher W D, Bauer K A et al.. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study.  J Thromb Haemost. 2005;  3 2479-2486
  CrossrefPubMedGoogle Scholar
• 44 Erikkson B I, Borris L, Dahl O E et al.. Oral, direct factor Xa inhibition with Bay 59-7939 for the prevention of venous thromboembolism after total hip replacement.  J Thromb Haemost. 2006;  4 121-128
  PubMedGoogle Scholar
• 45 Lee W M, Larrey D, Olsson R et al.. Hepatic findings in long term clinical trials of ximelagatran.  Drug Saf. 2005;  28 351-370
  CrossrefPubMedGoogle Scholar

Debra A HoppensteadtPh.D. 

Department of Pathology, Loyola University Chicago

2160 S. First Ave., Maywood, IL 60153

Email: dhoppen@lumc.edu